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Background
There is what might be termed an analysis gap between
scientific developments and understandings at the cellu-
lar and genetic levels which lead to new cancer treat-
ments and conventional statistical trial designs and
analyses that focus on demonstrating superiority or
non-inferiority.
Aim
To develop and apply multivariate mathematical/statistical
models that infer cell-kill and tumour re-growth dynamics
from durations of remission/response to cancer treatment.
Methods
A multivariate mathematical model was developed based
on a series of assumptions about the volume and distribu-
tion of residual disease remaining after treatment at the
population level, and its subsequent regrowth. This model
enables the results of randomised clinical trials to be eval-
uated in terms of effects on these biologically relevant
parameters.
Results
Examples will be given in a number of diseases but focus-
ing on breast cancer and the results from the AZURE
trial on the use of zoledronic acid, as well as from
CALGBB trial 9741 which evaluated a dose-dense treat-
ment strategy, as proposed by Norton and Simon. Results
will be presented, including quantification of the cell-
killing effect of zoledronic acid from the AZURE trial,
which demonstrate how the additional understandings
gained from such a modelling approach can aid in trial
design, interpretation of results, monitoring and analysis.
Conclusions
This modelling approach leads to new insights on the
mechanism of action of cancer treatments which stimu-
lates the development of new innovative approaches to
treatment and more appropriate targeting of treatments
to particular subgroups of patients.
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